Published in Health Business Week, November 17th, 2006
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Actavis.
Report 1: Actavis U.S., the United States manufacturing and marketing division of the international generic pharmaceutical company Actavis Group (ICEX: ACT), announced that it has received approval from the U.S. Food & Drug Administration to market Trimipramine Maleate Capsules.
Distribution of the product will commence immediately.
Trimipramine Maleate Capsules, the generic equivalent of Odyssey Pharmaceutical's Surmontil Capsules, are available in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.